Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Bioremedi AB
AB
Active
Org 5591318471
Tinnerbäcksgränd 12
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2017
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK 524K
+138% vs 2023
EBITDA margin
-9.8%
-166% vs 2023
Equity ratio
32.1%
Financial strength
Net profit 2024
SEK -51K
-191% vs 2023
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2020
0M
0%
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK 524K
+138%
EBITDA
SEK -51K
-166%
Net profit
SEK -51K
-191%
Total assets
SEK 216K
-10%
Equity
SEK 69K
-43%
Employees
0
—
Company information
Legal name
Bioremedi AB
Org number
5591318471
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
1 november 2017
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Undervisning, forskning och utveckling inom medicin.
Contact
Address
Tinnerbäcksgränd 12
Email
ali.moshfegh@bioedgetechnology.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Linköping
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
1M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
72
70
394
220
524
Staff expenses
—
—
—
—
−417
EBITDA
−74
1
314
78
−51
Depreciation & amort.
−0
—
—
—
—
EBIT
−74
1
314
78
−51
Net financials
—
−0
−25
−0
—
Profit before tax
−74
1
289
78
−51
Tax
−0
—
−16
−21
—
Net profit
−74
1
273
57
−51
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
73
65
419
239
216
Equity
50
51
325
121
69
Long-term debt
0
—
—
—
—
Short-term debt
23
14
95
118
147
Total debt
23
14
95
118
147
Financial ratios
5-year trend
EBITDA margin
-9.8%
This company
15.8%
Market median
-162% vs market
2020
2024
Equity ratio
32.1%
This company
38.2%
Market median
+16% vs market
2020
2024
Return on equity
-74.2%
This company
18.4%
Market median
-503% vs market
2020
2024
Net profit margin
-9.8%
This company
8.1%
Market median
-221% vs market
2020
2024
Asset turnover
2.42×
This company
1.12×
Market median
+116% vs market
2020
2024
Debt / equity
2.11×
This company
0.62×
Market median
-240% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (1)
ED
Elham Dadfar
Deputy Chief Executive Officer
Deputy Chief Executive Officer
2022
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
HD
Hossein Dadfar
Deputy Board Member
2022
AR
Ali Reza Moshfegh
Chairman
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Bioremedi AB also hold positions in
0
other companies.
Person
Role here
Other companies
Elham Dadfar
Deputy Chief Executive Officer
0 companies
Hossein Dadfar
Deputy Board Member
0 companies
Ali Reza Moshfegh
Chairman
0 companies